| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
110,820,000 |
| Market
Cap: |
1.18(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.58 - $25.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Precision Biosciences is a clinical stage gene editing company focused on improving life by developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its wholly owned proprietary ARCUS genome editing platform. Co. is simultaneously conducting a Phase 1/2a clinical trial evaluating PBCAR0191 as a potential first-in-class and a Phase 1 clinical trial evaluating PBCAR19B as, if approved, a potential CD19-targeting CAR T cell therapies in adult patients with relapsed or refractory, B-cell malignancies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
90,000 |
189,021 |
| Total Buy Value |
$0 |
$0 |
$43,200 |
$170,792 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
2,480 |
210,683 |
365,092 |
452,513 |
| Total Sell Value |
$25,523 |
$100,755 |
$167,195 |
$249,561 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
5 |
9 |
12 |
17 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kane Matthew R. |
President and CEO |
• • – |
2021-05-10 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
2,011,504 |
|
- |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-05-07 |
4 |
AS |
$8.57 |
$83,489 |
D/D |
(9,742) |
1,989,990 |
|
47% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-05-07 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
1,999,732 |
|
- |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-04-21 |
4 |
OE |
$1.18 |
$15,838 |
D/D |
13,422 |
1,978,218 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-04-19 |
4 |
AS |
$8.69 |
$84,084 |
D/D |
(9,676) |
4,016,759 |
|
34% |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-04-19 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
4,026,435 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-04-16 |
4 |
AS |
$8.84 |
$85,527 |
D/D |
(9,675) |
4,004,921 |
|
20% |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-04-16 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
4,014,596 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-04-15 |
4 |
AS |
$8.76 |
$84,762 |
D/D |
(9,676) |
3,993,082 |
|
14% |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-04-15 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
4,002,758 |
|
- |
|
| Frankel Stanley |
Director |
– • – |
2021-04-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,500 |
|
10% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-04-12 |
4 |
AS |
$8.67 |
$84,454 |
D/D |
(9,741) |
1,964,796 |
|
10% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-04-12 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
1,974,537 |
|
- |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-04-09 |
4 |
AS |
$8.87 |
$86,367 |
D/D |
(9,737) |
1,953,023 |
|
9% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-04-09 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
1,962,760 |
|
- |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-04-08 |
4 |
AS |
$9.00 |
$87,624 |
D/D |
(9,736) |
1,941,246 |
|
5% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-04-08 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
1,950,982 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-03-18 |
4 |
AS |
$11.08 |
$107,088 |
D/D |
(9,665) |
3,981,244 |
|
-5% |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-03-18 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
3,990,909 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-03-17 |
4 |
AS |
$10.92 |
$105,542 |
D/D |
(9,665) |
3,969,395 |
|
-15% |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-03-17 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
3,979,060 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-03-16 |
4 |
AS |
$11.97 |
$115,642 |
D/D |
(9,661) |
3,957,546 |
|
-10% |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-03-16 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
3,967,207 |
|
- |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-03-12 |
4 |
AS |
$11.36 |
$110,328 |
D/D |
(9,712) |
1,929,468 |
|
-8% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-03-12 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
1,939,180 |
|
- |
|
179 Records found
|
|
Page 5 of 8 |
|
|
0.29 (2.65%) 
